Literature DB >> 9749575

Autosomal dominant Parkinson's disease and alpha-synuclein.

M H Polymeropoulos1.   

Abstract

Multiple factors have been hypothesized over the years to be contributory and/or causative for Parkinson's disease (PD). Hereditary factors, although originally discounted, have recently emerged in the focus of PD research. The study of a large Italian family with PD using a genome scan approach led to the mapping of a PD susceptibility gene to the 4q21-q23 genomic region, where the gene for alpha-synuclein was previously mapped. Mutation analysis of the alpha-synuclein in four unrelated families with PD revealed a missense mutation segregating with the illness. Alpha-synuclein is an abundant presynaptic protein in the human brain with unknown function. It is conceivable that the mutation identified in the PD families may result in self-aggregation and/or decreased degradation of the protein, leading to the development of intracytoplasmic inclusion bodies and eventually to neuronal cell death. Moreover, the discovery of a mutation in the synuclein gene may offer us new insights in the understanding of the pathways that lead to neuronal degeneration.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9749575     DOI: 10.1002/ana.410440710

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  14 in total

Review 1.  Parkinson's disease dementia and potential therapeutic strategies.

Authors:  John N Caviness; LihFen Lue; Charles H Adler; Douglas G Walker
Journal:  CNS Neurosci Ther       Date:  2010-12-28       Impact factor: 5.243

2.  Dynamic reassembly of peptide RADA16 nanofiber scaffold.

Authors:  Hidenori Yokoi; Takatoshi Kinoshita; Shuguang Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-06       Impact factor: 11.205

3.  Effects of environmental tobacco smoke on adult rat brain biochemistry.

Authors:  Brian F Fuller; Mark S Gold; Kevin K W Wang; Andrew K Ottens
Journal:  J Mol Neurosci       Date:  2009-12-04       Impact factor: 3.444

Review 4.  Neuroprotective strategies in Parkinson's disease : an update on progress.

Authors:  Silvia Mandel; Edna Grünblatt; Peter Riederer; Manfred Gerlach; Yona Levites; Moussa B H Youdim
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

5.  Peripheral monocyte entry is required for alpha-Synuclein induced inflammation and Neurodegeneration in a model of Parkinson disease.

Authors:  Ashley S Harms; Aaron D Thome; Zhaoqi Yan; Aubrey M Schonhoff; Gregory P Williams; Xinru Li; Yudong Liu; Hongwei Qin; Etty N Benveniste; David G Standaert
Journal:  Exp Neurol       Date:  2017-11-16       Impact factor: 5.330

6.  Therapeutic effects of rapamycin on MPTP-induced Parkinsonism in mice.

Authors:  Kangyong Liu; Nan Shi; Yinyi Sun; Ting Zhang; Xiaojiang Sun
Journal:  Neurochem Res       Date:  2012-11-02       Impact factor: 3.996

7.  The anticholinesterase phenserine and its enantiomer posiphen as 5'untranslated-region-directed translation blockers of the Parkinson's alpha synuclein expression.

Authors:  Sohan Mikkilineni; Ippolita Cantuti-Castelvetri; Catherine M Cahill; Amelie Balliedier; Nigel H Greig; Jack T Rogers
Journal:  Parkinsons Dis       Date:  2012-05-29

Review 8.  Mammalian phospholipase D: Function, and therapeutics.

Authors:  M I McDermott; Y Wang; M J O Wakelam; V A Bankaitis
Journal:  Prog Lipid Res       Date:  2019-12-09       Impact factor: 16.195

Review 9.  Brain sites of movement disorder: genetic and environmental agents in neurodevelopmental perturbations.

Authors:  T Palomo; R J Beninger; R M Kostrzewa; T Archer
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.978

Review 10.  Physiological and pathological role of alpha-synuclein in Parkinson's disease through iron mediated oxidative stress; the role of a putative iron-responsive element.

Authors:  David Olivares; Xudong Huang; Lars Branden; Nigel H Greig; Jack T Rogers
Journal:  Int J Mol Sci       Date:  2009-03-17       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.